Mesoblast Off-the-Shelf Stem Cells Advance to Phase III
By Staff Reports
Friday, July 8, 2011
The FDA has cleared Mesoblast Ltd., of Melbourne, Australia, to begin a Phase III trial of its off-the-shelf mesenchymal precursor cells. The goal of the trial will be to reproduce positive results from a pilot trial at the University of Texas MD Anderson Cancer Center. In that study, the product was found to accelerate neutrophil and platelet recovery, with high 100-day patient survival and low rates of graft vs. host disease (GVHD).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.